DE60034954D1 - Substrate und screeningverfahren für transportproteine - Google Patents

Substrate und screeningverfahren für transportproteine

Info

Publication number
DE60034954D1
DE60034954D1 DE60034954T DE60034954T DE60034954D1 DE 60034954 D1 DE60034954 D1 DE 60034954D1 DE 60034954 T DE60034954 T DE 60034954T DE 60034954 T DE60034954 T DE 60034954T DE 60034954 D1 DE60034954 D1 DE 60034954D1
Authority
DE
Germany
Prior art keywords
transport proteins
methods
substrate
screening process
screening
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60034954T
Other languages
English (en)
Inventor
William J Dower
Mark Gallop
Ronald W Barrett
Kenneth C Cundy
Tania Chernov-Rogan
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
XenoPort Inc
Original Assignee
XenoPort Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by XenoPort Inc filed Critical XenoPort Inc
Application granted granted Critical
Publication of DE60034954D1 publication Critical patent/DE60034954D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5082—Supracellular entities, e.g. tissue, organisms
    • G01N33/5088—Supracellular entities, e.g. tissue, organisms of vertebrates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/0004—Screening or testing of compounds for diagnosis of disorders, assessment of conditions, e.g. renal clearance, gastric emptying, testing for diabetes, allergy, rheuma, pancreas functions
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C271/00—Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
    • C07C271/06—Esters of carbamic acids
    • C07C271/08—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms
    • C07C271/10—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C271/22—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms to carbon atoms of hydrocarbon radicals substituted by carboxyl groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
    • C07D271/02—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
    • C07D271/08—1,2,5-Oxadiazoles; Hydrogenated 1,2,5-oxadiazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
    • C07D311/06—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 2
    • C07D311/08—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 2 not hydrogenated in the hetero ring
    • C07D311/16—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 2 not hydrogenated in the hetero ring substituted in position 7
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/04—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length on carriers
    • C07K1/047—Simultaneous synthesis of different peptide species; Peptide libraries
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1034—Isolating an individual clone by screening libraries
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1034—Isolating an individual clone by screening libraries
    • C12N15/1086—Preparation or screening of expression libraries, e.g. reporter assays
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/531—Production of immunochemical test materials
    • G01N33/532—Production of labelled immunochemicals
    • G01N33/533—Production of labelled immunochemicals with fluorescent label
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/566—Immunoassay; Biospecific binding assay; Materials therefor using specific carrier or receptor proteins as ligand binding reagents where possible specific carrier or receptor proteins are classified with their target compounds
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/92—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving lipids, e.g. cholesterol, lipoproteins, or their receptors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2603/00—Systems containing at least three condensed rings
    • C07C2603/02—Ortho- or ortho- and peri-condensed systems
    • C07C2603/04—Ortho- or ortho- and peri-condensed systems containing three rings
    • C07C2603/06—Ortho- or ortho- and peri-condensed systems containing three rings containing at least one ring with less than six ring members
    • C07C2603/10—Ortho- or ortho- and peri-condensed systems containing three rings containing at least one ring with less than six ring members containing five-membered rings
    • C07C2603/12—Ortho- or ortho- and peri-condensed systems containing three rings containing at least one ring with less than six ring members containing five-membered rings only one five-membered ring
    • C07C2603/18—Fluorenes; Hydrogenated fluorenes
    • C—CHEMISTRY; METALLURGY
    • C40—COMBINATORIAL TECHNOLOGY
    • C40B—COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
    • C40B40/00—Libraries per se, e.g. arrays, mixtures

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biotechnology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Genetics & Genomics (AREA)
  • Physics & Mathematics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Analytical Chemistry (AREA)
  • Cell Biology (AREA)
  • Pathology (AREA)
  • Medicinal Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Endocrinology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Plant Pathology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Diabetes (AREA)
  • Animal Behavior & Ethology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Rheumatology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
DE60034954T 1999-09-14 2000-09-14 Substrate und screeningverfahren für transportproteine Expired - Lifetime DE60034954D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US15407199P 1999-09-14 1999-09-14
PCT/US2000/025439 WO2001020331A1 (en) 1999-09-14 2000-09-14 Substrates and screening methods for transport proteins

Publications (1)

Publication Number Publication Date
DE60034954D1 true DE60034954D1 (de) 2007-07-05

Family

ID=22549879

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60034954T Expired - Lifetime DE60034954D1 (de) 1999-09-14 2000-09-14 Substrate und screeningverfahren für transportproteine

Country Status (6)

Country Link
US (2) US7413536B1 (de)
EP (1) EP1212619B1 (de)
AT (1) ATE363074T1 (de)
AU (1) AU7703400A (de)
DE (1) DE60034954D1 (de)
WO (1) WO2001020331A1 (de)

Families Citing this family (62)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2003530329A (ja) * 2000-04-07 2003-10-14 ユニヴァーシティ オブ メリーランド，ボルチモア 増大したバイオアベイラビリティを有する胆汁酸含有プロドラッグ
US6858596B2 (en) 2000-08-05 2005-02-22 Smithkline Beecham Corporation Formulation containing anti-inflammatory androstane derivative
GB0019172D0 (en) 2000-08-05 2000-09-27 Glaxo Group Ltd Novel compounds
US6750210B2 (en) 2000-08-05 2004-06-15 Smithkline Beecham Corporation Formulation containing novel anti-inflammatory androstane derivative
US6777400B2 (en) 2000-08-05 2004-08-17 Smithkline Beecham Corporation Anti-inflammatory androstane derivative compositions
US6787532B2 (en) 2000-08-05 2004-09-07 Smithkline Beecham Corporation Formulation containing anti-inflammatory androstane derivatives
US6777399B2 (en) 2000-08-05 2004-08-17 Smithkline Beecham Corporation Anti-inflammatory androstane derivative compositions
US6759398B2 (en) 2000-08-05 2004-07-06 Smithkline Beecham Corporation Anti-inflammatory androstane derivative
US6858593B2 (en) 2000-08-05 2005-02-22 Smithkline Beecham Corporation Anti-inflammatory androstane derivative compositions
US6900192B2 (en) 2000-10-06 2005-05-31 Xenoport, Inc. Bile-acid conjugates for providing sustained systemic concentrations of drugs
UA77656C2 (en) 2001-04-07 2007-01-15 Glaxo Group Ltd S-fluoromethyl ester of 6-alpha, 9-alpha-difluoro-17-alpha-[(2-furanylcarbonyl)oxy]-11-beta-hydroxy-16- alpha-methyl-3-oxoandrosta-1,4-dien-17-beta-carbothioacid as anti-inflammatory agent
US8048917B2 (en) 2005-04-06 2011-11-01 Xenoport, Inc. Prodrugs of GABA analogs, compositions and uses thereof
JP2005501013A (ja) 2001-06-11 2005-01-13 ゼノポート，インコーポレイテッド Ｇａｂａ類似体の全身濃度が持続するアミノ酸コンジュゲート
US6955888B2 (en) 2001-06-11 2005-10-18 Xenoport Methods of screening agents, conjugates or conjugate moieties for transport by a PEPT2 transporter
US7026166B2 (en) * 2002-01-22 2006-04-11 Chiron Corporation Fluorogenic dyes
CA2476423A1 (en) 2002-02-15 2003-08-28 Sympore Gmbh Conjugates of biologically active compounds, methods for their preparation and use, formulation and pharmaceutical applications thereof
WO2003099338A2 (en) 2002-05-17 2003-12-04 Xenoport, Inc. Amino acid conjugates providing for sustained systemic concentrations of gaba analogues
FR2840994B1 (fr) * 2003-01-22 2008-07-18 Commissariat Energie Atomique Methode de criblage de banques de biomolecules et ses applications
US7541157B2 (en) 2002-05-31 2009-06-02 Commissariat A L'energie Atomique Method of screening groups of radioactive molecules and applications thereof
FR2840407B1 (fr) * 2002-05-31 2008-07-18 Commissariat Energie Atomique Methode de criblage de banques de biomolecules et ses applications
GB2389530B (en) 2002-06-14 2007-01-10 Cipla Ltd Pharmaceutical compositions
US20040161424A1 (en) * 2002-10-08 2004-08-19 Xenoport Human organic solute transporters
EP1567169A4 (de) 2002-11-04 2009-10-21 Xenoport Inc Gemcitabin-prodrugs, phramazeutische zusammensetzungen und verwendungen davon
US7704756B2 (en) 2003-01-21 2010-04-27 Novartis Vaccines And Diagnostics, Inc. Fluorogenic dyes
WO2005075992A1 (en) * 2004-01-30 2005-08-18 Xenoport, Inc. Mct1 transporter expressed in blood brain barrier cells
MXPA06011679A (es) * 2004-04-09 2007-01-23 Chugai Pharmaceutical Co Ltd Novedosos profarmacos solubles en agua.
WO2006017352A1 (en) 2004-07-12 2006-02-16 Xenoport, Inc. Amino acid derived prodrugs of propofol, compositions and uses thereof
US7241807B2 (en) 2004-07-12 2007-07-10 Xenoport, Inc. Prodrugs of propofol, compositions and uses thereof
TW200744603A (en) 2005-08-22 2007-12-16 Chugai Pharmaceutical Co Ltd Novel anticancer concomitant drug
JP2009510198A (ja) * 2005-09-26 2009-03-12 インヴィトロジェン コーポレーション 紫色レーザー励起性色素及びその使用方法
BRPI0708010A2 (pt) * 2006-01-31 2011-05-17 Sanofi Aventis método para a determinação da atividade do transportador de cátions orgánicos
WO2007098037A2 (en) 2006-02-17 2007-08-30 The Board Of Trustees Of The Leland Stanford Junior University Sequential reporter enzyme luminescence (srl) methods and compositions for practicing the same
US9238687B2 (en) 2006-04-13 2016-01-19 Chugai Seiyaku Kabushiki Kaisha Method for recombinant production of a desired polypeptide using a mammalian cell co-expressing a taurine transporter polypeptide
US8058260B2 (en) 2006-05-22 2011-11-15 Xenoport, Inc. 2′-C-methyl-ribofuranosyl cytidine prodrugs, pharmaceutical compositions and uses thereof
US20080213377A1 (en) * 2006-12-08 2008-09-04 Bhatia Sangeeta N Delivery of Nanoparticles and/or Agents to Cells
US20100233759A1 (en) 2007-03-15 2010-09-16 Chugai Seiyaku Kabushiki Kaisha Method for production of polypeptide
DK2186905T3 (en) 2007-08-07 2016-09-19 Chugai Pharmaceutical Co Ltd Method of Preparation of Heterogeneous Protein
RU2486245C2 (ru) 2007-10-15 2013-06-27 Чугаи Сейяку Кабусики Кайся Способ получения клетки, способной продуцировать гетеропротеины с высоким выходом
AU2008314973C1 (en) 2007-10-24 2014-05-08 Chugai Seiyaku Kabushiki Kaisha A cell for use in production of heteroproteins and production method using the same
WO2009129305A2 (en) 2008-04-15 2009-10-22 Tsrl, Inc. Prodrugs of neuraminidase inhibitors
KR102091207B1 (ko) 2009-02-13 2020-03-20 엑스-켐, 인크. Ｄｎａ―코딩된 라이브러리의 생성 및 스크리닝 방법
AU2010213497A1 (en) * 2009-02-13 2011-08-25 X-Body, Inc. Identification of nucleic acid delivery vehicles using DNA display
US8741601B2 (en) 2009-04-22 2014-06-03 Chugai Seiyaku Kabushiki Kaisha Method for producing a cell capable of high-yield production of heteroproteins
BR112012001043A2 (pt) * 2009-07-16 2016-03-15 Beckman Coulter Inc tinturas fluorescentes e uso das mesmas
JP5561692B2 (ja) * 2010-03-09 2014-07-30 国立大学法人群馬大学 新規蛍光化合物およびそれを用いた細胞内コレステロールの検出方法
US20110294767A1 (en) 2010-05-26 2011-12-01 Satiogen Pharmaceuticals, Inc. Bile acid recycling inhibitors and satiogens for treatment of diabetes, obesity, and inflammatory gastrointestinal conditions
US8399262B2 (en) 2011-03-23 2013-03-19 Darrel A. Mazzari Biosensor
EA032438B1 (ru) 2011-09-07 2019-05-31 Икс-Чем, Инк. Способы мечения днк-кодированных библиотек
DK2771003T3 (en) 2011-10-28 2017-07-17 Lumena Pharmaceuticals Llc Bile acid recycling inhibitors for the treatment of pediatric cholestatic liver disease
SG10201903512SA (en) 2011-10-28 2019-05-30 Lumena Pharmaceuticals Inc Bile Acid Recycling Inhibitors For Treatment Of Pediatric Cholestatic Liver Diseases
NZ739931A (en) 2012-07-13 2019-08-30 X Chem Inc Dna-encoded libraries having encoding oligonucleotide linkages not readable by polymerases
JP2016514684A (ja) 2013-03-15 2016-05-23 ルメナ ファーマシューティカルズ エルエルシー 原発性硬化性胆管炎および炎症性腸疾患の処置のための胆汁酸再循環阻害剤
CA2907214A1 (en) 2013-03-15 2014-09-18 Lumena Pharmaceuticals, Inc. Bile acid recycling inhibitors for treatment of barrett's esophagus and gastroesophageal reflux disease
US9988624B2 (en) 2015-12-07 2018-06-05 Zymergen Inc. Microbial strain improvement by a HTP genomic engineering platform
US11208649B2 (en) 2015-12-07 2021-12-28 Zymergen Inc. HTP genomic engineering platform
CA3007635A1 (en) 2015-12-07 2017-06-15 Zymergen Inc. Promoters from corynebacterium glutamicum
EP3478833A4 (de) 2016-06-30 2019-10-02 Zymergen, Inc. Verfahren zum erzeugen einer bakteriellen hämoglobin-bibliothek und deren verwendung
WO2018005793A1 (en) * 2016-06-30 2018-01-04 Zymergen Inc. Methods for generating a glucose permease library and uses thereof
GB2552460A (en) * 2016-07-11 2018-01-31 Evox Therapeutics Ltd CPP-Mediated EV Loading
JP2022520121A (ja) 2019-02-12 2022-03-28 ミルム ファーマシューティカルズ インコーポレイテッド 胆汁うっ滞を治療する方法
US20230146782A1 (en) * 2019-08-06 2023-05-11 Du Jessica Xinyun Deoxycholic acid compounds, pharmaceutical compositions and uses thereof
CN115176155A (zh) 2019-10-25 2022-10-11 塞卡科实验室有限公司 指示剂化合物、包括指示剂化合物的装置及其制备和使用方法

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
US5569678A (en) * 1989-07-31 1996-10-29 Massachusetts Institute Of Technology Control of wound scar production
DE3930696A1 (de) 1989-09-14 1991-03-28 Hoechst Ag Gallensaeurederivate, verfahren zu ihrer herstellung, verwendung als arzneimittel
US5866123A (en) * 1990-04-13 1999-02-02 Research Development Foundation Gene encoding cationic amino acid transporter protein
US5236902A (en) * 1990-11-26 1993-08-17 The Governors Of The University Of Alberta Method and probes for detecting nucleoside transporter and method for producing the probes
US5580775A (en) 1992-05-01 1996-12-03 Emory University High affinity, brain-specific nucleic acids encoding a L-proline transporter, and vectors, and host cells comprising the same
US5607691A (en) 1992-06-12 1997-03-04 Affymax Technologies N.V. Compositions and methods for enhanced drug delivery
DE4222315A1 (de) * 1992-07-05 1994-01-13 Inst Genbiologische Forschung DNA-Sequenzen für Aminosäuretransporter, Plasmide, Bakterien, Hefen und Pflanzen enthaltend einen Transporter
CA2115811A1 (en) 1993-02-17 1994-08-18 Claus Krebber A method for in vivo selection of ligand-binding proteins
US5658782A (en) * 1993-10-20 1997-08-19 State Of Oregon, Acting By And Through The Oregon State Board Of Higher Education On Behalf Of The Oregon Health Sciences University A Non-Profit Organization Amino acid transporters and uses
DE4343527A1 (de) * 1993-12-16 1995-06-22 Schering Ag Verfahren zur Identifizierung von Stoffen mit potentieller herbizider oder wachstumsregulatorischer Wirkung mittels pflanzlicher Transporterproteine, Verwendung der Transporterproteine sowie Substanzen mit herbizider und wachstumsregulatorischer Wirkung
US5589358A (en) * 1993-12-29 1996-12-31 Univ Wake Forest Ileal bile acid transporter compositions and methods
US5849525A (en) 1994-03-09 1998-12-15 Brigham And Women's Hospital, Inc. Compositions corresponding to a proton-coupled peptide transporter and methods of making and using same
AU3927795A (en) * 1994-11-12 1996-06-06 Basf Aktiengesellschaft Process for preparing amines from compounds with at least 3 cyano groups
US5824485A (en) * 1995-04-24 1998-10-20 Chromaxome Corporation Methods for generating and screening novel metabolic pathways
ATE382630T1 (de) 1995-09-11 2008-01-15 Jolla Cancer Res Found Moleküle, die sich in ausgewählten organen oder geweben in-vivo einfinden
AU705688B2 (en) * 1995-11-10 1999-05-27 Cytogen Corporation Peptides which enhance transport across tissues and methods of identifying and using the same
US5780264A (en) 1996-06-06 1998-07-14 The President And Fellows Of Harvard College Iron transport protein
EP0923603A1 (de) * 1996-07-16 1999-06-23 Novo Nordisk A/S Oligopeptid-transporter
US6361938B1 (en) 1996-11-08 2002-03-26 Elan Corporation, Plc Peptides which enhance transport across tissues and methods of identifying and using the same
WO1998038490A1 (en) * 1997-02-27 1998-09-03 Cellomics, Inc. A system for cell-based screening
US6057098A (en) 1997-04-04 2000-05-02 Biosite Diagnostics, Inc. Polyvalent display libraries
WO1998051325A2 (en) * 1997-05-15 1998-11-19 Cytogen Corporation Random peptides that bind to gastro-intestinal tract (git) transport receptors and related methods
WO1999003823A2 (en) 1997-07-15 1999-01-28 Oridigm Corporation Novel polyamine analogues as therapeutic and diagnostic agents

Also Published As

Publication number Publication date
AU7703400A (en) 2001-04-17
EP1212619A4 (de) 2004-12-08
ATE363074T1 (de) 2007-06-15
WO2001020331A1 (en) 2001-03-22
US7413536B1 (en) 2008-08-19
EP1212619A1 (de) 2002-06-12
US20090221442A1 (en) 2009-09-03
EP1212619B1 (de) 2007-05-23
WO2001020331A9 (en) 2002-10-03

Similar Documents

Publication Publication Date Title
DE60034954D1 (de) Substrate und screeningverfahren für transportproteine
DE60137203D1 (de) Poröse ferro- oder ferrimagnetische glasteilchen für molekültrennung
DE60017945D1 (de) Verfahren zur kryokonservierung von samenzellen
DE69433564D1 (de) Verbindungen die kolorektale krebszellen spezifisch binden und verfahren für ihre herstellung
DK2385141T3 (da) Flerkomponentnukleinsyreenzymer og fremgangsmåder til anvendelse heraf
DE60226797D1 (de) Instrument zum Einbringen von Befestigungselementen für Transplantate
DE69739856D1 (de) Agonisten für den rezeptor des hepatozyten-wachstumsfaktors und deren anwendungen
NO20043245L (no) Bindingsproteiner som biosensorer
DK1053256T3 (da) Antistoffer mod Dødsreceptor 4 (DR4) og anvendelser deraf
DE60126337D1 (de) Verfahren zum screenen für gpr40-liganden
ATE405841T1 (de) In-vitro-verfahren zum gleichzeitigen nachweisen und identifizieren von antibiotika unterschiedlicher klassen sowie entsprechender diagnostischer kit
ATE294164T1 (de) Fluoreszenzfarbstoffe zum festphasen- und flüssigphasen-screening
DK0921857T3 (da) Flerbröndsplader med lav baggrund til fluorescensmålinger af biologiske og biokemiske pröver
FI953990A (fi) Menetelmä nukleiinihappomonistusreaktiotuotteen tekemiseksi kykenemät-tömäksi olemaan lisämonistuksen kohteena, diagnostinen määritysmenetelmä, jossa tätä menetelmää käytetään, ja menetelmän tai määrityksen toteutukseen sopiva testipakkaus ja säiliö
DE69912839D1 (de) Nrihydroxstilbene enthaltende produkte und deren derivate und verfahren zur deren herstellung und ihre verwendung
DE59806371D1 (de) Kontrastmittel für das infarkt- und nekroseimaging
WO1999050459A3 (en) High throughput in vitro screening assays for transcription modulators
RS20100249A (en) CONJUGATES AND PROCEDURES FOR THEIR PRODUCTION, AND THEIR USE FOR THE TRANSPORT OF MOLECULES THROUGH BIOLOGICAL MEMBRANE
MXPA03011898A (es) Ensayo de seleccion in vitro para ?- secretasa.
MXPA03001536A (es) (aminoalcoxibenzoil) benzofuranos o benzotiofenos, metodo para preparar los mismo y composiciones que los contienen.
ATE501274T1 (de) Cucurbiturilderivat-gebundenes feststoffsubstrat und biochip unter verwendung davon
ATE252574T1 (de) Benzofuran-2-ones als färbemittel für organische materialien
DE69913533D1 (de) Reagentien für cyp2d fluoreszenztest
AU2001264163A1 (en) Lipid uptake assays
MY120085A (en) Pyrido-thieno-diazepines, method for the production thereof and pharmaceutical compositions containing said pyrido-thieno-diazepines.

Legal Events

Date Code Title Description
8332 No legal effect for de